U.S. Markets closed

Cytosorbents Corporation (CTSO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.42-0.29 (-2.99%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.71
Open9.71
Bid9.01 x 1000
Ask9.69 x 1300
Day's Range9.39 - 9.94
52 Week Range3.60 - 11.74
Volume399,450
Avg. Volume340,355
Market Cap406.715M
Beta (5Y Monthly)0.16
PE Ratio (TTM)N/A
EPS (TTM)-0.31
Earnings DateNov 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.88
  • CytoSorbents to Present at the Cowen 41st Annual Health Care Conference
    PR Newswire

    CytoSorbents to Present at the Cowen 41st Annual Health Care Conference

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Cowen 41st Annual Health Care Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD will present a brief overview of the Company's progress and outlook followed by a fireside chat with Joshua Jennings, MD, Managing Director, Senior Research Analyst, Equity Research at Cowen and Company. Company management will also meet with investors in 1x1 meetings throughout the day. To schedule a meeting with management, please contact your Cowen representative.

  • CytoSorbents 2021:  Leadership and Growth in the "New Normal"
    PR Newswire

    CytoSorbents 2021: Leadership and Growth in the "New Normal"

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Chief Executive Officer, Dr. Phillip Chan. Additional detail will be forthcoming in the Company's Q4 and Full Year 2020 earnings press release and Form 10-K, expected March 9, 2021.

  • CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference
    PR Newswire

    CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation in the 10th Annual SVB Leerink Global Healthcare Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will discuss the Company's progress and outlook with Danielle Antalffy, Managing Director, Medical Devices, Equity Research at SVB Leerink in a fireside chat format. Company management will also meet with investors in 1x1 meetings that are currently being scheduled, throughout the day. If interested, please contact your SVB Leerink representative.